Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.

Gabriel TremblayPatrick DanieleJanis BreezeLingling LiJatin ShahSharon ShachamMichael KauffmanMonika EngelhardtAjaj ChariAjay NookaDan VoglMaria GavriatopoulouMeletios-Athanasios DimopoulosPaul RichardsonNoa BiranDavid SiegelPhilip VlummensChantal DoyenThierry FaconMohamad MohtyNathalie MeulemanMoshe LevyLuciano CostaJames E HoffmanMichel DelforgeDavid KaminetzkyKatja WeiselMarc RaabDavid DingliSascha TuchmanFrenzel LaurentRavi VijGary SchillerPhilippe MoreauJoshua RichterMartin SchrederKlaus PodarTerri ParkerRobert Frank CornellKarlin LionelSylvain ChoquetJagannath Sundar

Published in: BMC cancer (2021)

This trial was registered on ClinicalTrials.gov under the trial-ID NCT02336815 on January 8, 2015.

Keyphrases

multiple myeloma
phase iii
study protocol
phase ii
clinical trial
randomized controlled trial
open label
newly diagnosed
combination therapy
replacement therapy